The increasing progress in using nano-biomaterials for medical purposes has opened new horizons toward researchers around the globe. To investigate the presence of these nanomaterials and the impacts they might have, a comparative enhanced-electrochemiluminescence immunosensing study has been designed. The effects of utilizing graphene oxide, silica, and gold nanoparticles in cancer diagnosis were evaluated during the quantification of two major cancer biomarkers (CEA and AFP) in different approaches. In other words, first and second approaches were designed to employ nanomaterials while third and fourth approaches were developed in absence of those. Accordingly, resulted LODs experienced dramatic amplification when nano-biomaterials were included in the immunosensor modification (for AFP: 1st and 3rd approaches: 1.36 fg/ml in comparison with 0.39 ng/ml, and for CEA: 2nd and 4th approaches: 1.90 fg/ml versus 0.46 ng/ml, respectively). Correspondingly, capability of nano-biomaterials for developing highly sensitive and more efficient immunosensors was validated through selectivity, stability, reproducibility, and feasibility examinations.

在医疗用途中使用纳米生物材料的日益进步为全球研究人员开辟了新的视野。为了研究这些纳米材料的存在及其可能产生的影响，已经设计了比较性的增强型化学发光免疫传感研究。在定量分析两种主要癌症生物标志物（CEA和AFP）的过程中，评估了利用氧化石墨烯，二氧化硅和金纳米颗粒在癌症诊断中的效果。换句话说，第一种和第二种方法被设计为采用纳米材料，而第三种和第四种方法是在没有纳米材料的情况下开发的。因此，当将纳米生物材料包括在免疫传感器修饰中时，最终的LOD经历了急剧的扩增（对于AFP：第一种和第三种方法：1.36 fg / ml，而0。39 ng / ml，对于CEA：第2和第4种方法：1.90 fg / ml对0.46 ng / ml。相应地，通过选择性，稳定性，可重复性和可行性检查，验证了纳米生物材料开发高度灵敏和更有效的免疫传感器的能力。